Vital Images Inc. announced the FDA has granted 510(k) clearance for 3D viewing through the VitreaView universal viewer.
Vital Images Inc., a Toshiba Medical Systems Group company, has received FDA 510(k) clearance for 3D viewing through the VitreaView universal viewer, the company announced.
The advanced visualization and analysis company introduced VitreaView in June 2011. The viewer is used as a communication tool for DICOM and non-DICOM medical images through a standardized viewer, so clinicians can access the images through various systems.
“Now with 3D and tablet capabilities available via VitreaView, our customers, particularly referring physicians and clinicians, have more functionality and easier access to the tools they need,” Erkan Akyuz, president and CEO of Vital Images, said in a statement. “Also, with access to images through the EMR as part of the Stage 2 Meaningful Use criteria, VitreaView integrated with a certified EMR enables the ability to meet this objective, with a toolset and infrastructure that also meets the needs of clinical users and IT administrators.”
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.